Scientists hunt for genes behind rare lung complication in liver bypass patients

NCT ID NCT07314814

Not yet recruiting Knowledge-focused Sponsor: Prof. Valérie Mc Lin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic variants that may explain why some people with a rare liver bypass condition (congenital portosystemic shunt) develop a serious lung complication called portopulmonary hypertension. Researchers will analyze blood samples from 120 patients and their close relatives. The goal is to better understand the genetic risk factors, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify patients at risk for portopulmonary hypertension earlier, allowing for proactive management.
What could go wrong: This is an observational genetic study, not a treatment trial. It may not find clear genetic links, and any future applications are far off.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL PORTOSYSTEMIC SHUNT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital portosystemic shunt pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL PORTOSYSTEMIC SHUNT PORTOPULMONARY HYPERTENSION PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Locations

University Hospitals Geneva / University of Geneva

Geneva, Canton of Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.